Jyong Biotech Ltd. Ordinary Shares(MENS)Earnings, Financials & Key Ratios
MENS•NASDAQ
Price updated Jun 19, 2026
AboutJyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stagesShow more
- Revenue$0
- EBITDA-$2M+27.5%
- Net Income-$3M+31.4%
- EPS (Diluted)-0.04+31.4%
MENS Key Insights
Jyong Biotech Ltd. Ordinary Shares (MENS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MENS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MENS Price & Volume
Jyong Biotech Ltd. Ordinary Shares (MENS) stock price & volume — 10-year historical chart
Loading chart...
MENS Growth Metrics
Jyong Biotech Ltd. Ordinary Shares (MENS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-40.87%
5 Years-40.87%
3 Years-
Last Year-
MENS Peer Comparison
Jyong Biotech Ltd. Ordinary Shares (MENS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 OCGN | 419.77M | 1.24 | -5.39 | 8.83% | -16.05% | -1279.88% | ||
 ICLR | 11.18B | 146.00 | 50.34 | -0.37% | 5.98% | 5.2% | 0.39 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 | |
 MEDP | 13.14B | 460.20 | 30.12 | 19.97% | 17.19% | 120.89% | 0.55 |
Compare MENS vs Peers
Jyong Biotech Ltd. Ordinary Shares (MENS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MENS Income Statement
Jyong Biotech Ltd. Ordinary Shares (MENS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 121K | 122K | 127K | 120K |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | -121K▲ 0% | -122K▼ 0.8% | -127K▼ 4.1% | -120K▲ 5.5% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | - | -0.83% | -4.1% | 5.51% |
Operating Expenses | 2.45M | 2.4M | 2.83M | 2.8M | 2.06M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 931K | 845K | 1.54M | 1.73M | 1.13M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 1.51M | 1.56M | 1.29M | 1.07M | 927K |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
Operating Income | -2.45M▲ 0% | -2.4M▲ 1.7% | -2.83M▼ 17.7% | -2.8M▲ 1.1% | -2.06M▲ 26.5% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | 1.72% | -17.68% | 1.13% | 26.49% |
EBITDA | -2.34M | -2.28M | -2.71M | -2.67M | -1.94M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | 2.31% | -18.58% | 1.33% | 27.49% |
D&A (Non-Cash Add-back) | 110K | 122K | 123K | 127K | 120K |
EBIT | -2.45M | -3.36M | -5.87M | -3.64M | -1.98M |
Net Interest Income | -832K | -829K | -760K | -701K | -1.03M |
Interest Income | 0 | 6K | 5K | 56K | 7K |
Interest Expense | 832K | 835K | 765K | 757K | 1.03M |
Other Income/Expense | 530K | -1.79M | -3.8M | -1.6M | -963K |
Pretax Income | -1.92M▲ 0% | -4.2M▼ 119.1% | -6.63M▼ 57.9% | -4.4M▲ 33.6% | -3.02M▲ 31.4% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.92M▲ 0% | -4.2M▼ 119.1% | -6.63M▼ 57.9% | -4.4M▲ 33.6% | -3.02M▲ 31.4% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | -119.1% | -57.93% | 33.63% | 31.39% |
Net Income (Continuing) | -1.92M | -4.2M | -6.63M | -4.4M | -3.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.03▲ 0% | -0.06▼ 106.0% | -0.09▼ 58.0% | -0.06▲ 33.6% | -0.04▲ 31.4% |
EPS Growth % | - | -105.97% | -57.97% | 33.6% | 31.43% |
EPS (Basic) | -0.03 | -0.06 | -0.09 | -0.06 | -0.04 |
Diluted Shares Outstanding | 71.57M | 76.03M | 76.03M | 76.03M | 76.03M |
Basic Shares Outstanding | 71.57M | 76.03M | 76.03M | 76.03M | 76.03M |
Dividend Payout Ratio | - | - | - | - | - |
MENS Balance Sheet
Jyong Biotech Ltd. Ordinary Shares (MENS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|
Total Current Assets | 6.22M | 2.65M | 2.46M | 1.84M | 206K |
Cash & Short-Term Investments | 4.22M | 2.38M | 812K | 177K | 98K |
Cash Only | 3.56M | 551K | 718K | 177K | 98K |
Short-Term Investments | 664K | 1.83M | 94K | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 1.6M | 263K | 1.65M | 1.66M | 108K |
Total Non-Current Assets | 6.62M | 6.78M | 6.28M | 6.41M | 6.16M |
Property, Plant & Equipment | 6.61M | 6.78M | 6M | 3.54M | 3.19M |
Fixed Asset Turnover | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 10K | 8K | 283K | 2.87M | 2.97M |
Total Assets | 12.84M▲ 0% | 9.43M▼ 26.6% | 8.74M▼ 7.3% | 8.25M▼ 5.7% | 6.37M▼ 22.8% |
Asset Turnover | - | - | - | - | - |
Asset Growth % | - | -26.56% | -7.28% | -5.68% | -22.82% |
Total Current Liabilities | 5.78M | 6.29M | 12.91M | 14.26M | 12.13M |
Accounts Payable | 25K | 46K | 4K | 2K | 3K |
Days Payables Outstanding | - | 138.76 | 11.97 | 5.75 | 9.13 |
Short-Term Debt | 4.83M | 4.93M | 7.65M | 7.97M | 7.28M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 151K | 23K | 4.22M | 4.99M | 3.33M |
Current Ratio | 1.08x | 0.42x | 0.19x | 0.13x | 0.02x |
Quick Ratio | 1.08x | 0.42x | 0.19x | 0.13x | 0.02x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 26.27M | 26.46M | 25.47M | 28.06M | 30.76M |
Long-Term Debt | 8.29M | 6.26M | 6.32M | 8.52M | 10.68M |
Capital Lease Obligations | 359K | 346K | 115K | 69K | 16K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 17.62M | 19.86M | 19.04M | 19.47M | 20.06M |
Total Liabilities | 32.05M | 32.76M | 38.38M | 42.32M | 42.88M |
Total Debt | 13.6M | 11.79M | 14.25M | 16.69M | 18.14M |
Net Debt | 10.04M | 11.24M | 13.53M | 16.51M | 18.04M |
Debt / Equity | - | - | - | - | - |
Debt / EBITDA | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - |
Interest Coverage | -2.94x | -2.88x | -3.70x | -3.69x | -1.99x |
Total Equity | -19.2M▲ 0% | -23.32M▼ 21.5% | -29.63M▼ 27.0% | -34.07M▼ 15.0% | -36.52M▼ 7.2% |
Equity Growth % | - | -21.46% | -27.04% | -14.99% | -7.18% |
Book Value per Share | -0.27 | -0.31 | -0.39 | -0.45 | -0.48 |
Total Shareholders' Equity | -19.2M | -23.32M | -29.63M | -34.07M | -36.52M |
Common Stock | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -14.83M | -19.03M | -25.66M | -30.06M | -33.08M |
Treasury Stock | -16.37M | -16.37M | -16.37M | -16.37M | -16.37M |
Accumulated OCI | 189K | 266K | 590K | 548K | 1.12M |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
MENS Cash Flow Statement
Jyong Biotech Ltd. Ordinary Shares (MENS) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|
Cash from Operations | -1.09M | -1.98M | -2.97M | -2.6M | -3.62M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -82.52% | -49.75% | 12.45% | -39.33% |
Net Income | -1.92M | -4.2M | -6.63M | -4.4M | -3.02M |
Depreciation & Amortization | 110K | 122K | 123K | 127K | 120K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 694K | 849K | 599K | 554K | 761K |
Working Capital Changes | 25K | 1.24M | 2.94M | 1.12M | -1.49M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 21K | -28K | -2K | 1K |
Cash from Investing | 731K | -1.31M | 1.39M | 95K | 0 |
Capital Expenditures | -88K | -137K | -246K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 819K | 0 | 0 | 0 | 0 |
Cash from Financing | 4.91M | -1.38M | 3.33M | 2.03M | 1.99M |
Debt Issued (Net) | 2.39M | -1.35M | 3.61M | 2.47M | 2.2M |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 2.52M | -35K | -276K | -445K | -213K |
Net Change in Cash | 5.16M▲ 0% | -4.61M▼ 189.3% | 1.72M▲ 137.4% | -532K▼ 130.9% | -1.64M▼ 208.5% |
Free Cash Flow | -1.18M▲ 0% | -2.12M▼ 80.5% | -3.22M▼ 51.7% | -2.6M▲ 19.1% | -3.62M▼ 39.3% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | -80.51% | -51.67% | 19.15% | -39.33% |
FCF per Share | -0.02 | -0.03 | -0.04 | -0.03 | -0.05 |
FCF Conversion (FCF/Net Income) | 0.57x | 0.47x | 0.45x | 0.59x | 1.20x |
Interest Paid | 88K | 106K | 162K | 104K | 223K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 |
MENS Key Ratios
Jyong Biotech Ltd. Ordinary Shares (MENS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Interest Coverage | -2.94x | -2.88x | -3.70x | -3.69x | -1.99x |
FCF Conversion | 0.57x | 0.47x | 0.45x | 0.59x | 1.20x |
Related:MENS Dividend History·MENS Revenue History·MENS Price History·MENS P/E History·MENS Financial Ratios·MENS Institutional Holders
MENS Frequently Asked Questions
Jyong Biotech Ltd. Ordinary Shares (MENS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Jyong Biotech Ltd. Ordinary Shares (MENS) grew revenue by 0.0% over the past year. Growth has been modest.
Jyong Biotech Ltd. Ordinary Shares (MENS) reported a net loss of $0.0M for fiscal year 2024.
Dividend & Returns
Jyong Biotech Ltd. Ordinary Shares (MENS) had negative free cash flow of $0.0M in fiscal year 2024, likely due to heavy capital investments.